This is a preview of subscription content, log in via an institution to check access.
References
Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009 (in press).
Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.
Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009 (in press).
Acquaviva C, Gelsi-Boyer V, Birnbaum D . Myelodysplastic syndromes: lost between two states? Leukemia 2009 (in press).
Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008; 8: 299–314.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905–911.
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343–1345.
Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113: 6403–6410.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144–147.
Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838–842.
Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haermatologica 2009 (in press).
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDS). Blood 2009; 114: 3285–3291.
Falini B . Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New Engl J Med 2005; 352: 254–266.
Acknowledgements
This work was supported by the Inserm, Institut Paoli-Calmettes and grants from the Association pour la Recherche contre le Cancer (AM, no. 4929) and Fondation de France (DB, Comité Leucémie).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carbuccia, N., Trouplin, V., Gelsi-Boyer, V. et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 24, 469–473 (2010). https://doi.org/10.1038/leu.2009.218
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.218
- Springer Nature Limited
This article is cited by
-
Epigenetic regulation by ASXL1 in myeloid malignancies
International Journal of Hematology (2023)
-
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
Cancer Cell International (2021)
-
Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion
Head and Neck Pathology (2021)
-
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Journal of Molecular Medicine (2020)
-
RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
Journal of Hematology & Oncology (2019)